GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Quick Facts
What This Study Found
8718 GLP-1RA-associated tumors were reported, with significant signals for thyroid and pancreatic cancers.
Key Numbers
How They Did This
The study utilized disproportionality analysis on FAERS data from 2004 to 2021 to assess the relationship between GLP-1RAs and tumor occurrences.
Why This Research Matters
Understanding the potential risks associated with GLP-1RAs is crucial for patient safety, especially given their widespread use in diabetes management. This research provides valuable insights for clinicians regarding the monitoring of tumor-related adverse effects.
What This Study Doesn't Tell Us
The study relies on reported data, which may be subject to underreporting or misclassification of cases.
Trust & Context
- Original Title:
- GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
- Published In:
- Frontiers in pharmacology, 13, 925377 (2022)
- Authors:
- Yang, Zheng, Lv, Yuhuan, Yu, Meng, Mei, Mei, Xiang, Linyu, Zhao, Subei, Li, Rong
- Database ID:
- RPEP-06631
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06631APA
Yang, Zheng; Lv, Yuhuan; Yu, Meng; Mei, Mei; Xiang, Linyu; Zhao, Subei; Li, Rong. (2022). GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.. Frontiers in pharmacology, 13, 925377. https://doi.org/10.3389/fphar.2022.925377
MLA
Yang, Zheng, et al. "GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.." Frontiers in pharmacology, 2022. https://doi.org/10.3389/fphar.2022.925377
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonist-associated tumor adverse events: A re..." RPEP-06631. Retrieved from https://rethinkpeptides.com/research/yang-2022-glp1-receptor-agonistassociated-tumor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.